Join free
Sign inSign up free
← Back to Blog
Research Roundup13 min read

The Cholesterol Pill That's Secretly a Peptide: Enlicitide, Explained

The Cholesterol Pill That's Secretly a Peptide: Enlicitide, Explained

We recently wrote about how orforglipron, the first oral GLP-1 pill, turned out not to be a peptide — it's a small molecule. Enlicitide is the mirror-image surprise: a once-daily cholesterol pill that is, more or less, a peptide. Specifically a macrocyclic one, engineered to survive your gut and actually get absorbed, which is the thing peptides famously can't usually do.

It's a good window into where peptide drug development is actually heading — away from "injectable powder you have to reconstitute" and toward "pill you swallow." Here's the breakdown.

What enlicitide is

Enlicitide (full name enlicitide decanoate, made by Merck) is an investigational oral PCSK9 inhibitor. PCSK9 is a protein that regulates how many LDL receptors your liver keeps on its cells. LDL receptors are what pull "bad" LDL cholesterol out of your blood. Block PCSK9, and your liver keeps more receptors around, and more LDL gets cleared. [1]

This is not a new target. There are already PCSK9 inhibitors on the market — drugs like evolocumab (Amgen's Repatha) and alirocumab (Sanofi and Regeneron's Praluent), plus inclisiran (Novartis's Leqvio), a twice-yearly siRNA shot. But those are all injectables. Enlicitide aims to do the same job as a daily pill. [2][3]

One detail worth getting right, because it's the whole point: Merck doesn't actually call this "a peptide." Their official description is a "novel small molecule macrocyclic peptide." [1] That hybrid label is deliberate. It's a peptide by composition and a small-molecule-like drug by behavior, and it sits right on the line the whole field is trying to redraw. Which brings us to the actual story.

Why "a peptide in a pill" is the real story

Peptides are great drugs and terrible pills. They're chains of amino acids, and your digestive system is purpose-built to chop chains of amino acids into pieces. That's why almost every peptide drug — semaglutide, the GLP-1s, BPC-157 — has historically been an injection. Your gut would destroy them.

Building a pill that blocks PCSK9 was, for a long time, considered close to impossible. The protein's surface is the kind of broad, flat interface that small molecules struggle to grab onto. [4] Enlicitide gets around all of this two ways. First, it's a macrocyclic peptide — the chain loops back on itself into a ring, which makes it far more resistant to the enzymes that would otherwise shred it. Merck's chemists reported building the molecule through a modular fragment-assembly approach, tuning it to low picomolar potency while fixing the solubility and stability problems that sank earlier candidates. [5] Second, the formulation pairs it with a permeation enhancer, sodium caprate, that helps it cross the gut wall into the bloodstream. The combination is what lets a peptide behave like a pill.

This is the same engineering challenge the whole field is racing to solve, and it ties directly into the retatrutide drug-vs-biologic classification fight we covered, where "what counts as a peptide" turns out to have real regulatory teeth. Enlicitide's "small molecule macrocyclic peptide" label is that fight in miniature.

The backstory: this used to be called MK-0616

Enlicitide didn't appear out of nowhere. It's the rebranded MK-0616, and the earlier data is part of why the Phase 3 results landed with so little drama.

In Phase 1, single oral doses knocked down free PCSK9 by more than 93%, and two weeks of daily dosing dropped LDL-C by over 60%. [6] Then came the Phase 2b trial (NCT05261126), which tested 6, 12, 18, and 30 mg against placebo in adults with high cholesterol. At eight weeks, the placebo-adjusted LDL-C reduction reached up to 60.9%, and the drug was well tolerated. [7] Those results, published in JACC in 2023, are what greenlit the full Phase 3 program at a 20 mg dose.

The data: it actually works (three trials, not one)

Merck ran enlicitide through the CORALreef Phase 3 program — over 19,000 participants total across the whole effort. [1] Three pivotal trials have now read out, all positive:

CORALreef Lipids (about 2,900 adults; 2,909 randomized 2:1 to 20 mg or placebo across 168 sites in 14 countries): LDL-C dropped 55.8% in the primary analysis, and 59.7% in a post-hoc reanalysis, versus placebo at week 24, with reductions sustained out to a year. [1][8] Published in the New England Journal of Medicine (Navar et al., 2026). [8]

CORALreef HeFH (303 adults with heterozygous familial hypercholesterolemia, the inherited high-cholesterol disorder): LDL-C fell 59.4% versus placebo at week 24, on top of background statins, and held over one year. It also cut non-HDL-C, ApoB, and lipoprotein(a). [9][10] This is the trial that matters most for the patients who need PCSK9 inhibition the most. Published in JAMA (Ballantyne et al., January 2026). [11]

CORALreef AddOn (301 statin-treated adults, head-to-head against the actual oral alternatives): enlicitide cut LDL-C by 64.6% from baseline at day 56, well past ezetimibe (27.8%), bempedoic acid plus ezetimibe (36.5%), and bempedoic acid alone (6.3%, lower than usual, which the investigators attributed to the high-intensity statin background). [12][13] More striking than the averages: 81.2% of enlicitide patients hit an LDL under 70 mg/dL with at least a 50% drop, versus 2%, 8%, and 22% for the comparators. [14] Published in JACC (Catapano et al., 2026). [15]

For perspective, injectable PCSK9 inhibitors lower LDL-C by up to about 70%. [16] So a pill landing in the high-50s to mid-60s is genuinely competitive with an injection. That's the headline cardiologists reacted to.

But here's the honest catch, and it's the most important thing to understand about all three trials: every one of them measures LDL-C, a surrogate. None of them proves enlicitide prevents heart attacks. That question belongs to a fourth, much larger study — CORALreef Outcomes (NCT06008756), which has finished enrolling over 14,500 patients and isn't projected to wrap until December 2029. [9][8] Lower LDL is strongly tied to fewer cardiovascular events as a class effect, so the expectation is good, but the hard proof for this specific drug is years out, well after any likely approval. That's the caveat to keep front and center.

It's also worth flagging how big the addressable problem is. By Merck's own framing, hypercholesterolemia affects roughly 73 million US adults and is a leading driver of cardiovascular death. [7] (You'll also see an "86 million" figure quoted — that's the CDC's broader count of US adults with total cholesterol over 200 mg/dL, a different measure.) A pill that works as well as an injection removes a real adherence barrier.

The wrinkle nobody puts in the headline: you have to take it on an empty stomach

Food wrecks enlicitide's absorption. In pharmacokinetic studies, taking a 40 mg dose after a high-fat breakfast cut its exposure to roughly a third, and its peak concentration to about a quarter, of what fasted dosing achieved. [17] So the drug has to be taken on an empty stomach, with continued fasting afterward. Trial adherence was above 95%, but trials are a controlled environment; pharmacists have flagged that real-world effectiveness will lean heavily on patients getting the timing right. [14]

This is also where the competition gets interesting. AstraZeneca's AZD0780, an oral small-molecule PCSK9 inhibitor, posted a 50.7% LDL-C reduction at 30 mg in its Phase 2b PURSUIT trial, and AstraZeneca is explicitly marketing it as something you can take without fasting restrictions. [18][19] Enlicitide is well ahead — AZD0780 is a phase behind and still chasing [20] — but the fasting requirement is the one place a rival can land a clean punch.

Where it stands

Enlicitide is investigational, not yet FDA-approved. As of the latest reporting, Merck has three positive Phase 3 trials in hand but had not yet formally submitted its application, and the drug has no PDUFA date. [16] What it does have is a Commissioner's National Priority Voucher (CNPV), which the FDA awarded in December 2025. [12] The CNPV is a new and fairly opaque program that promises one-to-two-month reviews instead of the usual ten to twelve. [21] FDA documents pointed to an expected submission around April 2026, and analysts at RBC floated the possibility of approval as early as fall 2026, though Merck hasn't committed to a public timeline. [22][21]

Merck Research Labs president Dr. Dean Li framed the ambition bluntly: the goal, he said, is to "democratize PCSK9" and make it as routine as taking aspirin. [4] Analysts have called the drug a multi-billion-dollar, potential-blockbuster opportunity, largely because the injectable PCSK9 class has terrific efficacy but mediocre uptake, and a pill could finally fix that. [23]

The takeaway for peptide-watchers

Enlicitide matters less because of cholesterol specifically and more because of what it proves: a peptide can be engineered into an effective oral drug that rivals an injectable. Pair that with orforglipron — a small molecule doing a peptide's job as a pill — and you can see both halves of the same trend: the line between "peptide" and "pill" blurring from both directions. Merck's own "small molecule macrocyclic peptide" label is the tell.

For anyone tracking the research-peptide space, this is the legitimate, FDA-pipeline end of the field doing exactly what the gray market only gestures at: making these compounds work, the right way, with the trials to prove it — fasting requirements, surrogate-endpoint caveats, multi-year outcomes studies and all. We'll keep enlicitide in the research library as it moves toward approval.

This article summarizes publicly reported clinical-trial data for educational purposes and is not affiliated with or endorsed by Merck. Enlicitide is investigational and not FDA-approved. For research purposes only. Not for human consumption. Not medical advice. Always consult a licensed physician.

Sources

  1. Merck. "Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial." merck.com
  2. AJMC. "Oral PCSK9 Inhibitor Enlicitide Matches Injectables in Lowering LDL Cholesterol." ajmc.com
  3. Powers Health / The New York Times. "New Merck Pill Cuts Bad Cholesterol by 60%, Potentially Replacing Injections." powershealth.org
  4. The New York Times, via Powers Health (Dr. Dean Li, "democratize PCSK9"). powershealth.org
  5. "Discovery Process of Enlicitide, a Highly Engineered Macrocyclic Peptide Therapeutic, through Issue-Driven Fragment-Based Synthetic Assembly and SAR." Journal of Medicinal Chemistry. pubs.acs.org
  6. "Emerging oral therapeutic strategies for inhibiting PCSK9" (Phase 1 PK/PD of enlicitide decanoate). PMC. pmc.ncbi.nlm.nih.gov
  7. Merck. "Merck's MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study" (Ballantyne et al., JACC 2023, NCT05261126). merck.com
  8. Navar AM, Mikhailova E, Catapano AL, et al. "A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide." New England Journal of Medicine. 2026;394(6):529-539. doi:10.1056/NEJMoa2511002 (CORALreef Lipids, NCT05952856). acc.org summary
  9. Merck. "Merck's Enlicitide Decanoate… Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial" (includes CORALreef Outcomes enrollment, NCT06008756). merck.com
  10. Patient Care Online. "Investigational Oral PCSK-9 Inhibitor Reduces LDL-C by 60% in Late-Stage HeFH Trial." patientcareonline.com
  11. Ballantyne CM, Gellis L, Tardif JC, et al. "Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial." JAMA. 2026;335(2):129-139. doi:10.1001/jama.2025.20620 (NCT05952869). clinicaltrials.gov
  12. Merck. "Merck's Enlicitide Decanoate… Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins" (CORALreef AddOn; CNPV awarded December 2025). merck.com
  13. American College of Cardiology. "CORALreef AddOn: Novel PCSK9 Inhibitor Reduces LDL-C in Patients Not Meeting Goals." acc.org
  14. Pharmacy Times. "New Oral Contender Outshines Standard Add-on Therapies for LDL-C" (goal attainment; empty-stomach / post-dose fasting administration). pharmacytimes.com
  15. Catapano AL, Mikhailova E, Navar AM, et al. "Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial." J Am Coll Cardiol. 2026. doi:10.1016/j.jacc.2026.03.036 (NCT06450366). clinicaltrials.gov
  16. AJMC. "Oral PCSK9 Inhibitor Enlicitide Lowers LDL by 57% at 24 Weeks" (injectables up to ~70%; no FDA submission/PDUFA date as of publication). ajmc.com
  17. "Emerging oral therapeutic strategies for inhibiting PCSK9" (food-effect data, sodium caprate permeation enhancer). ScienceDirect. sciencedirect.com
  18. Pharmacy Times. "AZD0780, Novel Oral PCSK9 Inhibitor, Demonstrates Major LDL Cholesterol Reductions" (PURSUIT Phase 2b, 50.7% at 30 mg). pharmacytimes.com
  19. AstraZeneca. "AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial" (no fasting restriction). astrazeneca.com
  20. FierceBiotech. "AstraZeneca's oral PCSK9 inhibitor halves cholesterol in phase 2 trial" (AZD0780 behind Merck's MK-0616). fiercebiotech.com
  21. BioSpace. "Merck's Cholesterol Pill Delivers 'Antibody-Like Efficacy' After Earning FDA Voucher" (CNPV review timelines; RBC fall-2026 estimate). biospace.com
  22. Reuters via Yahoo Finance. "US FDA taps Merck drugs with blockbuster sales potential for national priority vouchers" (expected April 2026 submission). finance.yahoo.com
  23. PharmaVoice. "5 FDA drug approvals to watch in 2026" (blockbuster potential; poor injectable uptake). pharmavoice.com
Failed to fetch